论文部分内容阅读
目的:探讨乳腺癌根治术后不同时间开始化疗对患者临床预后的影响。方法:自2012年1月—2013年1月,前瞻性收集我院收治的乳腺癌患者100例,根据患者术后化疗时间,将患者分为观察组(开始时间<3周)和对照组(开始时间3~<8周)。主要观察指标包括临床疗效(无进展生存期、生存率和复发率)和安全性(治疗相关并发症和健康相关的生存质量)。结果:与对照组相比,观察组患者无进展生存期明显延长(P=0.049);3年复发率明显降低(20.00%vs.38.00%,P=0.047)。两组患者生存率无统计学差异(94.00%vs.92.00%,P=1.000)。观察组患者术后1年健康相关的生存质量显著高于对照组[(73.00±12.16)vs.(64.64±10.58),t=3.677,P=0.000]。两组患者主要治疗相关并发症包括骨髓抑制、贫血、腹泻、恶心和呕吐等差异均无统计学意义(P>0.05)。结论:术后早期化疗有助于延长乳腺癌患者无进展生存期,改善患者术后生存质量。
Objective: To investigate the effect of chemotherapy on the clinical prognosis of patients with breast cancer at different times after radical operation. Methods: From January 2012 to January 2013, 100 cases of breast cancer were prospectively collected in our hospital. According to the postoperative chemotherapy time, patients were divided into observation group (initial time <3 weeks) and control group ( Start time 3 ~ <8 weeks). MAIN OUTCOME MEASURES Includes clinical efficacy (progression-free survival, survival and relapse rates) and safety (treatment-related complications and health-related quality of life). Results: Compared with the control group, the progression-free survival in the observation group was significantly longer (P = 0.049). The recurrence rate at 3 years was significantly lower (20.00% vs.38.00%, P = 0.047). There was no significant difference in survival between the two groups (94.00% vs 92.00%, P = 1.000). The health-related quality of life of observation group one year after operation was significantly higher than that of control group [(73.00 ± 12.16) vs. (64.64 ± 10.58), t = 3.677, P = 0.000]. There were no significant differences in the main treatment-related complications between the two groups, including myelosuppression, anemia, diarrhea, nausea and vomiting (P> 0.05). Conclusion: Early postoperative chemotherapy can help prolong the progression-free survival of patients with breast cancer and improve postoperative quality of life.